UB Paderborn / Katalog / Suche / in CDI

P260 Improvement in treatment satisfaction among patients with PIDD on an investigational 20% subcutaneous immunoglobulin therapy

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S99-S99

2016

Volltextzugriff (PDF)

P257 Treatment preference among patients with primary immunodeficiency diseases (PIDD) on investigational 20% subcutaneous immunoglobulin therapy

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S98-S99

2016

Volltextzugriff (PDF)

O015 Tolerability of a new human immune globulin subcutaneous, 20% preparation in primary immunodeficiency diseases

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S5-S6

2016

Volltextzugriff (PDF)

P252 Results of a phase 2/3 study of SCIG 20% in PIDD patients in North America

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S97-S97

2016

Volltextzugriff (PDF)

P251 Safety/tolerability of human immune globulin subcutaneous, 20% in pediatric patients with primary immunodeficiency diseases

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S97-S97

2016

Volltextzugriff (PDF)

Innocuité et tolérabilité de l’immunoglobuline humaine G à 20 %, administrée par voie sous-cutanée (Ig20Gly) : analyse finale d’une étude de phase 2/3 portant sur des patients souffrant de déficits immunitaires primitifs (DIP) en Europe

La revue de medecine interne, 2018-12, Vol.39, p.A188-A188

2018

Volltextzugriff (PDF)

P254 Local adverse reactions decreased over time during IGHY treatment in patients with PIDD

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S97-S98

2016

Volltextzugriff (PDF)

Sécurité d’emploi, efficacité et tolérance à long terme de la perfusion sous-cutanée d’immunoglobulines G facilitée par la hyaluronidase humaine recombinante chez des enfants et des adultes atteints de déficit immunitaire primitif (DIP)

La revue de medecine interne, 2017-06, Vol.38, p.A172-A172

2017

Volltextzugriff (PDF)

P253 Safety and tolerability of SCIG 20% in patients with PIDD in europe and north america

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S97-S97

2016

Volltextzugriff (PDF)

Is It Hyper Ige Syndrome Or Something Else? A Patient With Chromosome 18q Deletion

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB160-AB160

2012

Volltextzugriff (PDF)

Innocuité et tolérabilité d’une préparation d’immunoglobuline humaine sous-cutanée à 20 % chez des patients pédiatriques âgés < 16 ans souffrant de déficits immunitaires primitifs (DIP) en Europe et en Amérique du Nord

La revue de medecine interne, 2018-12, Vol.39, p.A187-A188

2018

Volltextzugriff (PDF)

Role of NF-κB signaling pathway in increased tumor necrosis factor-α-induced apoptosis of lymphocytes in aged humans

Cell death and differentiation, 2005-02, Vol.12 (2), p.177-183

2005

Volltextzugriff (PDF)

Les résultats intérimaires d’une étude non interventionnelle de sécurité post-AMM (PASS) sur la sécurité à long terme de l’IgSCf 10 % perfusion facilitée avec la Hyaluronidase humaine recombinée (rHuPH20) chez les patients atteints de Déficit Immunitaire

La revue de medecine interne, 2017-12, Vol.38, p.A165-A166

2017

Volltextzugriff (PDF)

P251 STEADY-STATE SERUM IGG TROUGH LEVELS IS ADEQUATE FOR PHARMACOKINETIC ASSESSMENT IN IMMUNOGLOBULIN-TREATED PATIENTS WITH IMMUNODEFICIENCIES

Annals of allergy, asthma, & immunology, 2019-11, Vol.123 (5), p.S45-S46

2019

Volltextzugriff (PDF)

Differential sensitivity of naïve and subsets of memory CD4+ and CD8+ T cells to hydrogen peroxide-induced apoptosis

Genes and immunity, 2007-10, Vol.8 (7), p.560-569

2007

Volltextzugriff (PDF)

Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway

Genes and immunity, 2002-08, Vol.3 (5), p.270-278

2002

Volltextzugriff (PDF)

Evaluation of Immunological Features in IgM Deficiency

Journal of allergy and clinical immunology, 2006-02, Vol.117 (2), p.S109-S109

2006

Volltextzugriff (PDF)

Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination

Nature immunology, 2003-10, Vol.4 (10), p.1023-1028

2003

Volltextzugriff (PDF)

H2AX gene does not have a modifier effect on ataxia-telangiectasia phenotype

International journal of immunogenetics, 2011-06, Vol.38 (3), p.209-213

2011

Volltextzugriff (PDF)

IG20GLY TOLERABILITY AND INFUSION CHARACTERISTICS ACROSS AGE GROUPS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES

Annals of allergy, asthma, & immunology, 2018-11, Vol.121 (5), p.S48-S49

2018

Volltextzugriff (PDF)

Thimersoal causes mitochondrial microenvironment change in neuronal cells

Journal of allergy and clinical immunology, 2003-02, Vol.111 (2), p.S320-S320

2003

Volltextzugriff (PDF)

P281 Adverse events and infusion parameters of IG20GLY in PIDD patients whose pre-study treatment was IVIG

Annals of allergy, asthma, & immunology, 2017-11, Vol.119 (5), p.S71-S72

2017

Volltextzugriff (PDF)

P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

Annals of allergy, asthma, & immunology, 2017-11, Vol.119 (5), p.S71-S71

2017

Volltextzugriff (PDF)

Combined immunodeficiency in a patient with chromosome 1q42.1q42.3 deletion

Journal of allergy and clinical immunology, 2005-02, Vol.115 (2), p.S79-S79

2005

Volltextzugriff (PDF)

Role of NF-kappaB signaling pathway in increased apoptosis of lymphocytes in aged humans

Journal of allergy and clinical immunology, 2004-02, Vol.113 (2), p.S215-S215

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

P260 Improvement in treatment satisfaction among patients with PIDD on an investigational 20% subcutaneous immunoglobulin therapy

P257 Treatment preference among patients with primary immunodeficiency diseases (PIDD) on investigational 20% subcutaneous immunoglobulin therapy

O015 Tolerability of a new human immune globulin subcutaneous, 20% preparation in primary immunodeficiency diseases

P252 Results of a phase 2/3 study of SCIG 20% in PIDD patients in North America

P251 Safety/tolerability of human immune globulin subcutaneous, 20% in pediatric patients with primary immunodeficiency diseases

Innocuité et tolérabilité de l’immunoglobuline humaine G à 20 %, administrée par voie sous-cutanée (Ig20Gly) : analyse finale d’une étude de phase 2/3 portant sur des patients souffrant de déficits immunitaires primitifs (DIP) en Europe

P254 Local adverse reactions decreased over time during IGHY treatment in patients with PIDD

Sécurité d’emploi, efficacité et tolérance à long terme de la perfusion sous-cutanée d’immunoglobulines G facilitée par la hyaluronidase humaine recombinante chez des enfants et des adultes atteints de déficit immunitaire primitif (DIP)

P253 Safety and tolerability of SCIG 20% in patients with PIDD in europe and north america

Is It Hyper Ige Syndrome Or Something Else? A Patient With Chromosome 18q Deletion

Innocuité et tolérabilité d’une préparation d’immunoglobuline humaine sous-cutanée à 20 % chez des patients pédiatriques âgés < 16 ans souffrant de déficits immunitaires primitifs (DIP) en Europe et en Amérique du Nord

Role of NF-κB signaling pathway in increased tumor necrosis factor-α-induced apoptosis of lymphocytes in aged humans

Les résultats intérimaires d’une étude non interventionnelle de sécurité post-AMM (PASS) sur la sécurité à long terme de l’IgSCf 10 % perfusion facilitée avec la Hyaluronidase humaine recombinée (rHuPH20) chez les patients atteints de Déficit Immunitaire

P251 STEADY-STATE SERUM IGG TROUGH LEVELS IS ADEQUATE FOR PHARMACOKINETIC ASSESSMENT IN IMMUNOGLOBULIN-TREATED PATIENTS WITH IMMUNODEFICIENCIES

Differential sensitivity of naïve and subsets of memory CD4+ and CD8+ T cells to hydrogen peroxide-induced apoptosis

Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway

Evaluation of Immunological Features in IgM Deficiency

Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination

H2AX gene does not have a modifier effect on ataxia-telangiectasia phenotype

IG20GLY TOLERABILITY AND INFUSION CHARACTERISTICS ACROSS AGE GROUPS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES

Thimersoal causes mitochondrial microenvironment change in neuronal cells

P281 Adverse events and infusion parameters of IG20GLY in PIDD patients whose pre-study treatment was IVIG

P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

Combined immunodeficiency in a patient with chromosome 1q42.1q42.3 deletion

Role of NF-kappaB signaling pathway in increased apoptosis of lymphocytes in aged humans

Aktive Filter

Suchergebnisse filtern